Help us protect older babies and toddlers against respiratory infections in the future.

We are seeking babies and toddlers ages 6 months to less than 22 months to participate in a clinical study testing a nasal spray RSV vaccine.

RSV is a common seasonal virus that infects nearly all children. Most of the time it causes a mild illness, like a cold, but for some children it leads to more severe lung problems, such as bronchiolitis and pneumonia.

RSV vaccines have recently been approved for the older adult population, but no vaccine is available yet for children. Our youngest and most vulnerable patients still need a vaccine for RSV prevention.

Click to DOWNLOAD THE TRIAL LEAFLET to read more

LILAC is a trial investigating a new blood thinning medication called Abelacimab in patients with an irregular heartbeat at high-risk of stroke who have been deemed unsuitable for oral blood thinning medication.

Approximately 1900 people aged 65 years old and over will take part in this study around the world. The blood thinner is given via injection once a month, and patients followed up regularly to monitor their health and various other parameters. 

Eligible patients will be contacted by the surgery directly.

The purpose of this trial is to find out whether a new drug Survodutide helps people living with overweight or obesity and diabetes, to lose weight.

Approximately 20 people will participate in this trial in the UK and approximately 600 people worldwide. If needed, the worldwide total number of trial participants may be increased up to 850.

Participants receive weekly injections and are followed up regularly to monitor their weight and several other parameters to judge the effect.

Eligible patients will be contacted by the surgery. As noted above, very few patients will be able to join this trial.

A research study to find out if Inclisiran can help prevent cardiovascular events (such as heart attacks, strokes, emergency stenting procedures to improve blood flow) in adults who are at high cardiovascular risk but have not had a major cardiovascular event, and who also have high cholesterol. This is often referred to as “primary prevention”.

Having a lot of LDL-cholesterol (also known as “bad” cholesterol) in your blood can lead to build up on your artery walls (a condition called atherosclerotic cardiovascular disease), creating a thick and fatty deposit (or plaque) that can block blood flow. Blocked arteries can lead to important cardiovascular events, such as heart attack, stroke, or cardiovascular-related death.

Inclisiran has been shown to be safe and effective at lowering LDL-cholesterol. This study will help understand if a reduction in LDL-cholesterol with inclisiran will also prevent these important cardiovascular events from occurring.

Approximately 14,000 participants in approximately 45 countries will participate in this study.

Eligible patients will be contacted by the surgery - use the reply link in the text, or alternatively email 

THE TRIAL LEAFLET IS AVAILABLE HERE